Search

Showing "11154" results for ""

D for death, not A B or C, is main cause of decline in Ugandan HIV prevalence

Switching to an NRTI-sparing HAART regimen can reduce fat loss

Highly sensitive method uncovers high levels of resistance in mothers given single-dose nevirapine

Addition of capravirine to a three-drug regimen not beneficial in patients with NNRTI resistance

Single-dose nevirapine reduces HIV transmission in second delivery

Long-term CD4 increase on HAART averages 250-350 cells, plateaus after 3-4 years

The ‘New York case’: details revealed at Boston conference

Pregnancy doubles the risk of HIV infection

Switch to tenofovir better than change to abacavir?

Pregnant women with CD4 cell counts over 250 not at greater risk of nevirapine-related toxicity in Kenyan study

Therapeutic range for atazanavir defined

Three trials bring African mother to child transmission down to four per cent; WHO vows to reconsider guidelines

MRSA in HIV-positive patients often community acquired, associated with HIV disease severity

Therapeutic drug monitoring useful for improving treatment outcomes in many patients taking HAART

Six- and nine-month courses of TB treatment equivalent in Indian HIV-positive patients

Two new drug classes given to people with HIV for the first time

Little difference in child transmission rates between formula feed and breast-plus-AZT

Investigational NNRTI TMC278 swiftly cuts viral load in treatment-naive patients

Receive the latest HIV research and conference news

Showing "11154" results for ""

D for death, not A B or C, is main cause of decline in Ugandan HIV prevalence

Switching to an NRTI-sparing HAART regimen can reduce fat loss

Highly sensitive method uncovers high levels of resistance in mothers given single-dose nevirapine

Addition of capravirine to a three-drug regimen not beneficial in patients with NNRTI resistance

Single-dose nevirapine reduces HIV transmission in second delivery

Long-term CD4 increase on HAART averages 250-350 cells, plateaus after 3-4 years

The ‘New York case’: details revealed at Boston conference

Pregnancy doubles the risk of HIV infection

Switch to tenofovir better than change to abacavir?

Pregnant women with CD4 cell counts over 250 not at greater risk of nevirapine-related toxicity in Kenyan study

Therapeutic range for atazanavir defined

Three trials bring African mother to child transmission down to four per cent; WHO vows to reconsider guidelines

MRSA in HIV-positive patients often community acquired, associated with HIV disease severity

Therapeutic drug monitoring useful for improving treatment outcomes in many patients taking HAART

Six- and nine-month courses of TB treatment equivalent in Indian HIV-positive patients

Two new drug classes given to people with HIV for the first time

Little difference in child transmission rates between formula feed and breast-plus-AZT

Investigational NNRTI TMC278 swiftly cuts viral load in treatment-naive patients

Receive the latest HIV research and conference news